Results 101 to 110 of about 5,560 (153)

FGD3 mediates lytic cell death, enhancing efficacy and immunogenicity of chemotherapy agents in breast cancer. [PDF]

J Exp Clin Cancer Res
Zhu J, Dai X, Ghosh S, Wei E, Mao C, Jiang Q, Spaulding AJ, Mulligan MP, Romero R, Han YJ, Boudreau MW, Olopade O, Hergenrother PJ, Shapiro DJ.   +13 more
europepmc   +1 more source

Neural regulation of lung cancer: from mechanisms to clinical implications. [PDF]

Eur J Med Res
Xu L, Sun X, Yao Y, Fang H.
europepmc   +1 more source

Aprepitant use during chemotherapy and association with survival in women with early breast cancer [PDF]

J Natl Cancer Inst
Background Preclinical studies have shown that aprepitant, an antiemetic used to prevent chemotherapy-induced nausea and vomiting, slows mammary tumor growth and progression.
E. Botteri, Sarah Hjorth, Fabio Conforti, Vincenzo Bagnardi, B. K. Andreassen, N. Støer, Sameer Bhargava, G. Ursin, S. Gandini, Erica K. Sloan, Aeson Chang   +10 more
semanticscholar   +2 more sources

Reducing toxicity and enhancing efficacy of doxorubicin by liposomal doxorubicin and aprepitant in breast cancer [PDF]

Sci Rep
This study investigates the efficacy and toxicity profiles of pegylated liposomal doxorubicin (Doxil) compared to conventional doxorubicin. Additionally, it evaluates the potential of combination therapy involving Doxil and doxorubicin with aprepitant ...
A. Ghahremanloo, Bahareh Erfani, Fereshteh Asgharzadeh, Saeide Mansoori, Fatemeh Gheybi, S. Hashemy   +5 more
semanticscholar   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

A pharmacological overview of aprepitant for the prevention of postoperative nausea and vomiting

Expert Review of Clinical Pharmacology, 2023
Introduction Post-operative nausea and vomiting (PONV) affects 30% of all patients undergoing surgery and up to 80% of high-risk patients. Antiemetics for PONV prophylaxis target a variety of receptor systems, with varying degrees of efficacy and side ...
Andrew E. Padilla, A. Habib
semanticscholar   +1 more source

Topical formulations of Aprepitant are safe and effective in relieving pain and inflammation, and drive neural regeneration.

The ocular surface, 2023
PURPOSE To test long-term ocular toxicity and analgesic/anti-inflammatory efficacy of two novel ocular formulations of neurokinin 1 receptor (NK1R) antagonist Aprepitant.
Filippo Bonelli, Ibrahim Demirsoy, R. L. Lasagni Vitar, P. Fonteyne, G. Ferrari   +4 more
semanticscholar   +1 more source

Aprepitant

Hospital Pharmacy, 2003
Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada, Terri Levien, Danial E. Baker   +2 more
openaire   +1 more source

Efficacy of aprepitant as a prophylactic medication in adults with cyclic vomiting syndrome

Neurogastroenterology and Motility, 2023
Aprepitant is a neurokinin‐1 receptor antagonist, and recent guidelines by the American Neurogastoenterology and Motility Society recommend its use as prophylaxis in moderate‐to severe cyclic vomiting syndrome (CVS).
Milan Patel, Omeed Partovi, H. Mooers, Katja Kovacic, Zhuping Garacchi, T. Venkatesan   +5 more
semanticscholar   +1 more source

The use of aprepitant for the prevention of postoperative nausea and vomiting in endoscopic transsphenoidal pituitary surgery

International Forum of Allergy and Rhinology, 2023
Postoperative nausea and vomiting (PONV) are adverse effects after surgery, which may increase the risk of complications. Aprepitant is a neurokinin‐1 receptor blocker and has been shown to reduce chemotherapy‐related nausea and vomiting and PONV ...
Daniel J. Lee, J. Douglas, Jeremy Chang, Jadyn A. Wilensky, C. Jackson, John Y. K. Lee, M. Grady, D. Yoshor, M. Kohanski, J. Palmer, J. Atkins, N. Adappa   +11 more
semanticscholar   +1 more source